# Pharma-Analysis
Executive-level sales analysis and AI-ready storytelling framework converting multi-year pharma data into customer-facing infographics.

![Infographic Overview](sources/Pharma Executive Strategic Performance Roadmap.png)

# ğŸ“Š Sales Performance & Growth Insights (2017â€“2022)

This repository contains an executive-level analytical summary and storytelling framework
used to convert a multi-year pharmaceutical sales report into professional infographics
for customer presentation.

---

## âš¡ Executive Summary

- **Timeframe:** 2017â€“2022 (6 years)
- **Scope:** 6 Channels, 92 Groups, 1000+ Accounts
- **Products:** 19 SKUs (Diabetes-focused portfolio)
- **Total Volume:** ~4.28M units
- **Total Revenue:** ~15.15M

**Key Channels by Revenue Share**
- Chains: **56.8%**
- Hospitals: **15.3%**
- Clinics / Other / Semi / Co-Op: Remaining share

---

## ğŸ” Key Business Challenges

- High volatility in 2018 (-35.8%) followed by strong rebound in 2019 (+126%)
- Slowing growth in recent years:
  - 2021: +10.2%
  - 2022: +5.4%
- Strong seasonality with weak performance in July, September, and December
- Low market penetration:
  - Only **~11.3%** of (Product Ã— Account Ã— Month) combinations generate sales

---

## ğŸ’¡ Strategic Insights

### 1ï¸âƒ£ Chains Are the Growth Engine
- Contribute **56.8%** of total revenue
- Major groups (Royal, Pharmazone, Yiaco) dominate performance

### 2ï¸âƒ£ Diabetes Portfolio Drives Value
- Glucophage XR 1000 alone contributes **~18.4%** of total revenue
- Diabetes basket represents over **50%** of portfolio value

### 3ï¸âƒ£ Growth Is Slowing
- Post-recovery growth is decelerating
- Indicates need for additional growth levers

### 4ï¸âƒ£ Clear Seasonal Opportunities
- Strong months: January, March, November
- Weak months: July, September, December
- Promotional timing can materially improve results

### 5ï¸âƒ£ Significant White Space
- Low product penetration across accounts
- Large opportunity for horizontal expansion (new doors)

---

## ğŸ¯ Actionable Recommendations

### ğŸš€ Growth Levers
- Annual agreements with top Chains
- Diabetes Care bundles (Glucophage XR + Glucovance)
- Cross-sell with Concor & Euthyrox

### ğŸ“ˆ Seasonal Activation
- Q4 promotional push (Octâ€“Dec)
- Doctor sampling & pharmacy incentives

### ğŸª Door Expansion Program
- Target Top-50 zero-sales accounts per region
- Track KPIs:
  - New Doors Sold / Month
  - 60-Day Repeat Rate

---

## ğŸ“Š Expected Impact

- **+2â€“4 pp** annual growth from channel & bundle optimization
- **10â€“15%** recovery of seasonal revenue loss
- Improved market penetration and revenue sustainability

---
